Determining the feasibility of objective adherence measurement with blister packaging smart technology

American Journal of Health-System Pharmacy

Volumn 69, Issue 10, 2012, Pages 872-879

  Van Onzenoort, Hein A ^a   Neef, Cees ^b   Verberk, Willem W ^c   Van Iperen, H Peter ^d   De Leeuw, Peter W ^b   Van Der Kuy, Paul Hugo M ^e  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Microlife Corporation   (Taiwan)

^d Confrérie Clinique SA ^*  (Switzerland)

^e Sittard Geleen Heerlen   (Netherlands)

Author keywords

Compliance; Hypotensive agents; Netherlands; Packaging; Patients; Pharmaceutical services; Pharmacy, community; Technology; Valsartan

Indexed keywords

VALSARTAN;

ARTICLE; BLISTER PACK; BLISTER PACK SMART TECHNOLOGY; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG INFORMATION; DRUG MONITORING; DRUG PACKAGING; FEASIBILITY STUDY; HUMAN; MAJOR CLINICAL STUDY; MICROPROCESSOR; PATIENT COMPLIANCE; PATIENT COUNSELING; PERFORMANCE; PHARMACY; PRINTING; PRIORITY JOURNAL; STANDARD; TABLET FORMULATION; TREATMENT DURATION;

EID: 84861463133     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100592     Document Type: Article

References (33)

1. Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens. 2001; 19:149-55.
2. Hughes DA, Bagust A, Haycox A et al. The impact of non-compliance on costeffectiveness of pharmaceuticals: a review of the literature. Health Econ. 2001; 10:601-15.
3. Urquhart J. Partial compliance in cardiovascular disease: risk implications. Br J Clin Pract Suppl. 1994; 73:2-12.
4. Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J. 1996; 17(suppl A):8-15. (Pubitemid 26129713)
5. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157:2413-56.
6. Ho PM, Magid DJ, Shetterly SM et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008; 155:772-9. (Pubitemid 351410514)
7. Ho PM, Magid DJ, Masoudi FA et al. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006; 6:48-56.
8. Ho PM, Rumsfeld JS, Masoudi FA et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006; 166:1836-41. (Pubitemid 44455165)
9. Gehi AK, Ali S, Na B et al. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Intern Med. 2007; 167:1798-803. (Pubitemid 47403069)
10. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidencebased pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007; 297:177-86. (Pubitemid 46089734)
11. Vrijens B, Vincze G, Kristanto P et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008; 336:1114-7. (Pubitemid 351731741)
12. Van Wijk BL, Shrank WH, Klungel OH et al. A cross-national study of the persistence of antihypertensive medication use in the elderly. J Hypertens. 2008; 26:145-53. (Pubitemid 350294860)
13. Caro JJ, Salas M, Speekman JL et al. Persistence with treatment for hypertension in actual practice. Can Med Assoc J. 1999; 160:31-7. (Pubitemid 29054224)
14. Bourgalt C, Sénécal M, Brisson M et al. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens. 2005; 19:607-13. (Pubitemid 41131661)
15. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother. 2009; 10:2973-85.
16. Liberopoulos EN, Florentin M, Mikhailidis DP et al. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf. 2008; 7:717-25.
17. Cramer JA, Benedict A, Muszbek N et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008; 62:76-87. (Pubitemid 350294021)
18. Schmittdiel JA, Uratsu CS, Karter AJ et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008; 23:588-94.
19. Burnier M, Schneider MP, Chiolero A et al. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decision. J Hypertens. 2001; 19:335-41. (Pubitemid 32116286)
20. Bertholet N, Favrat B, Fallab-Stubi CL et al. Why objective monitoring of compliance is important in the management of hypertension. J Clin Hypertens (Greenwich). 2000; 2:258-62.
21. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999; 21:1074-90. (Pubitemid 29326165)
22. Cramer JA, Mattson RH, Prevey ML et al. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989; 261:3272-7.
23. Rudd P, Ahmed S, Zachary V et al. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther. 1990; 48:676-85.
24. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet. 1997; 32:345-56. (Pubitemid 27199228)
25. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353:487-97. (Pubitemid 41127293)
26. Pullar T, Kumar S, Tindall H et al. Time to stop counting the tablets? Clin Pharmacol Ther. 1989; 47:547.
27. Matsui D, Hermann C, Klein JJ et al. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol. 1994; 34:944-9. (Pubitemid 24321081)
28. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997; 50:105-16. (Pubitemid 27089212)
29. Oakley D, Potter L, de Leon-Wong E et al. Oral contraceptive use and protective behavior after missed pills. Fam Plann Perspect. 1997; 29:277-9,287.
30. Santschi V, Wuerzner G, Schneider MP et al. Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring. Eur J Clin Pharmacol. 2007; 63:1179-84. (Pubitemid 350112756)
31. Yamada H, Nakashima M. New electronic device for monitoring medication compliance. Am J Health-Syst Pharm. 2003; 60:1910-1.
32. Jekle C, Krämer I. OtCM (Objective therapy Compliance Measurement): smart blister packages for measuring patient compliance. Hosp Pharm Eur. 2008; 40:47-50.
33. Van Onzenoort HA, Verberk WJ, Kessels AG et al. Assessing medication adherence simultaneously by electronic monitoring and pill count in patients with mild to moderate hypertension. Am J Hypertens. 2010; 23:149-54.